Treatment of Colorectal Cancer Using a Combination of Liposomal Irinotecan (Irinophore C™) and 5-Fluorouracil

• Jennifer I. Hare,

  Affiliation Department of Pharmacology, University of Alberta, Edmonton, Canada

  ⨯
• Robert W. Neijzen,

  Affiliation Department of Pharmaceutical Science, Universiteit Utrecht, Utrecht, Netherlands

  ⨯
• Malathi Anantha,

  Affiliation Experimental Therapeutics, BC Cancer Agency, Vancouver, Canada

  ⨯
• Nancy Dos Santos,

  Affiliation Experimental Therapeutics, BC Cancer Agency, Vancouver, Canada

  ⨯
• Natashia Harasym,

  Affiliation Centre for Drug Research and Development, Vancouver, Canada

  ⨯
• Murray S. Webb,

  Affiliation Centre for Drug Research and Development, Vancouver, Canada

  ⨯
• Theresa M. Allen,

  Affiliations Department of Pharmacology, University of Alberta, Edmonton, Canada, Centre for Drug Research and Development, Vancouver, Canada

  ⨯
• Marcel B. Bally,

  Affiliations Experimental Therapeutics, BC Cancer Agency, Vancouver, Canada, Centre for Drug Research and Development, Vancouver, Canada, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada

  ⨯
• Dawn N. Waterhouse

  * E-mail: dwater@bccrc.ca

  Affiliations Experimental Therapeutics, BC Cancer Agency, Vancouver, Canada, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada

  ⨯